Mark J. Ratain to Sarcoma
This is a "connection" page, showing publications Mark J. Ratain has written about Sarcoma.
Connection Strength
0.183
-
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs. 2011 Jun; 29(3):481-8.
Score: 0.076
-
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. Hum Genomics. 2008 Sep; 3(1):53-70.
Score: 0.069
-
Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol. 1991 May; 9(5):871-6.
Score: 0.021
-
A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res. 1989 Jun 01; 49(11):3129-33.
Score: 0.018